← Back to Briefing
Cancer Drug Developer Erasca Shares Plummet After Patient Death in Clinical Trial
Importance: 25/1001 Sources
Why It Matters
This incident underscores the critical importance of patient safety in drug development and the immediate, severe financial consequences for companies when clinical trials encounter serious adverse events.
Key Intelligence
- ■Erasca, a cancer drug developer, saw its shares drop by a record 55%.
- ■The significant stock decline followed a patient death during a clinical trial.
- ■This event highlights the inherent risks and volatility in the biotech and pharmaceutical sectors.